Richard F. Chambers
Algemeen Directeur bij Acxit Lifesciences GmbH
Profiel
Richard F.
Chambers is currently the Managing Director at Acxit Lifesciences GmbH and a Member-Supervisory Board at ProBioGen AG.
He previously served as a Director at anwerina AG, a Member-Supervisory Board at curasan AG from 2007 to 2017, and the Chief Financial Officer at Heidelberg Pharma AG.
He obtained his undergraduate degree from Technische Universität Darmstadt.
Actieve functies van Richard F. Chambers
Bedrijven | Functie | Begin |
---|---|---|
ProBioGen AG
ProBioGen AG Miscellaneous Commercial ServicesCommercial Services ProBioGen AG operates as a contract development and manufacturing organization. It specializes in cell line engineering, process development, and GMP manufacturing of biopharmaceuticals. The firm offers services such as cell line development, process development, manufacturing programs, physio-chemical analyses, and cell-based assays. The company was founded by Uwe Marx on June 13, 1994 and is headquartered in Berlin, Germany. | Directeur/Bestuurslid | - |
Acxit Lifesciences GmbH
Acxit Lifesciences GmbH Investment ManagersFinance Acxit Lifesciences GmbH provides financial and strategic advisory services. The private company is based in Frankfurt, Germany. Richard F. Chambers has been the CEO of the German company since 2004. | Algemeen Directeur | 01-01-2004 |
Eerdere bekende functies van Richard F. Chambers
Bedrijven | Functie | Einde |
---|---|---|
CURASAN AG | Directeur/Bestuurslid | 29-06-2017 |
HEIDELBERG PHARMA AG | Financieel Directeur/CFO | - |
anwerina AG
anwerina AG Miscellaneous Commercial ServicesCommercial Services Anwerina AG is a pharmaceutical company based in Germany that specializes in the development of quality drugs and medical technology for the treatment of bone diseases. The Swiss company is experts in the field of osteoporosis and have a patient-centered strategy for the development of unique and cost-effective drugs. The private company offers ASCENDRA® / ASCENDRA® DUO / ASCENDRA® TRIO, which is an injection solution used for the therapy of osteoporosis in postmenopausal women with an increased risk of fractures. The company also focuses on the development of generic drugs for patients with bone metastases in the field of oncology. | Directeur/Bestuurslid | - |
Opleiding van Richard F. Chambers
Technische Universität Darmstadt | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
HEIDELBERG PHARMA AG | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
ProBioGen AG
ProBioGen AG Miscellaneous Commercial ServicesCommercial Services ProBioGen AG operates as a contract development and manufacturing organization. It specializes in cell line engineering, process development, and GMP manufacturing of biopharmaceuticals. The firm offers services such as cell line development, process development, manufacturing programs, physio-chemical analyses, and cell-based assays. The company was founded by Uwe Marx on June 13, 1994 and is headquartered in Berlin, Germany. | Commercial Services |
curasan AG
curasan AG Pharmaceuticals: MajorHealth Technology curasan AG engages in the developing, manufacturing and marketing of regenerative medicine. Its products cover the fields of bone and tissue regeneration, tissue engineering, and wound healing for dental, spinal and orthopedic applications. The company was founded by Hans Dieter Rössler in 1988 and is headquartered in Frankfurt, Germany. | Health Technology |
anwerina AG
anwerina AG Miscellaneous Commercial ServicesCommercial Services Anwerina AG is a pharmaceutical company based in Germany that specializes in the development of quality drugs and medical technology for the treatment of bone diseases. The Swiss company is experts in the field of osteoporosis and have a patient-centered strategy for the development of unique and cost-effective drugs. The private company offers ASCENDRA® / ASCENDRA® DUO / ASCENDRA® TRIO, which is an injection solution used for the therapy of osteoporosis in postmenopausal women with an increased risk of fractures. The company also focuses on the development of generic drugs for patients with bone metastases in the field of oncology. | Commercial Services |
Acxit Lifesciences GmbH
Acxit Lifesciences GmbH Investment ManagersFinance Acxit Lifesciences GmbH provides financial and strategic advisory services. The private company is based in Frankfurt, Germany. Richard F. Chambers has been the CEO of the German company since 2004. | Finance |